Cargando…
Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
BACKGROUND: Older patients with HER2-positive metastatic breast (HER2 + MBC) cancer are underrepresented in clinical trials. We aim to describe the treatment patterns and overall survival (OS) for older women receiving trastuzumab for HER2 + MBC. METHODS: Retrospective, whole-of-population cohort st...
Autores principales: | Daniels, Benjamin, Kiely, Belinda E., Tang, Monica, Tervonen, Hanna, Pearson, Sallie-Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740010/ https://www.ncbi.nlm.nih.gov/pubmed/31510955 http://dx.doi.org/10.1186/s12885-019-6126-y |
Ejemplares similares
-
Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
por: Daniels, Benjamin, et al.
Publicado: (2021) -
Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018) -
Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)
por: Daniels, Benjamin, et al.
Publicado: (2018) -
Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
por: Tang, Monica, et al.
Publicado: (2019) -
Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
por: Tang, Monica, et al.
Publicado: (2020)